Best Strategies in Recurrent or Persistent Clostridium difficile Infection
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Clostridium difficile infection (CDI) is the primary cause of antibiotic-associated colitis and 15-25% of nosocomial antibiotic-associated diarrhea. Its clinical manifestations can range from mild diarrhea to toxic megacolon, bowel perforation, septic shock, and death. Over the past decade, more virulent strains have become increasingly common causes, and the incidence of CDI has risen, especially in elderly patients. These developments have led to an increase in recurrent CDI, which is more difficult to treat. This review focuses on recurrent CDI and its treatment. METHODS: MEDLINE review using search terms Clostridium difficile, Clostridium difficile infection, recurrent Clostridium difficile infection. RESULTS: A first recurrence may be treated with the same regimen as the first episode. Metronidazole 500 mg q 8 h for 10-14 days is the drug of choice for moderate infection, and vancomycin 125 mg q 6 h for 10-14 days is the drug of choice for severe CDI. Metronidazole should not be used for treatment of subsequent recurrences because of potential neurotoxicity and hepatic toxicity. Second recurrences should be treated with an oral vancomycin course and taper: 125 mg q 6 h × 10-14 days, 125 mg q 12 h × 7 days, 125 mg q 24 h × 7 days, 125 mg q 48-72 h × 2-8 weeks. Alternative agents are fecal bacteriotherapy, a "rifaximin chaser," nitazoxanide, probiotics, and intravenous immunoglobulin. Fidaxomicin has been approved recently. Monoclonal antibodies against C. difficile toxin remain investigational. CONCLUSION: Treatment of recurrent CDI remains challenging. Because of the lack of high-quality studies, recommendations for treatment are based on expert opinion. Metronidazole and vancomycin are the mainstays of treatment for both the initial infection and the first recurrence. For second recurrences, a vancomycin course plus taper is recommended. For subsequent recurrences, treatment options are many, with no one approach being entirely satisfactory. New drugs (fidaximicin) and treatments (monoclonal antibodies against the causative toxin) appear promising.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010 · cited 1×
“Patients with only an initial episode of CDI and control patients have a predominance of Bacteroides and Firmicutes, whereas patients who develop recurrent CDI have significantly less diversity [24].”
Cited by
Persistent bacterial infections and persister cells
Fisher, R. A., Gollan, B., & Helaine, S. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.42 · Cited by 1,243
Consequences of Clostridium difficile infection: understanding the healthcare burden
Bouza, E. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12064 · Cited by 220
“difficile and its toxins [41,43,44].”
Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options
Lo Vecchio, A., & Zacur, G. M. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32834bc9a9 · Cited by 183
Bakken, J. S., Polgreen, P. M., Beekmann, S. E., Riedo, F. X., & Streit, J. A. (2013) · Anaerobe · doi:10.1016/j.anaerobe.2013.08.007 · Cited by 63
“CDI usually responds to treatment with oral metronidazole or vancomycin, but between 5 and 35% of treated patients experience recurrent diarrhea in spite of appropriate therapy [3,4].”
Background
Metadata
- Authors
- Cocanour, C. S.
- Venue
- Surgical Infections
- Publisher
- SAGE Publications
- Published
- 2011-06
- Volume
- 12
- Issue
- 3
- Pages
- 235-239
- ISSN
- 1096-2964 (ISSN-L)
- 1557-8674
- OpenAlex
- W2043678651
- Cited by
- 42
- References
- 1
- FWCI
- 5.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Best Strategies in Recurrent or Persistent Clostridium difficile Infection. https://app.cochat.ai/papers/10.1089/sur.2010.080
- The paper
- Cocanour, C. S. (2011). Best Strategies in Recurrent or Persistent Clostridium difficile Infection. Surgical Infections. https://doi.org/10.1089/sur.2010.080
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.